Artal Group S.A. Tango Therapeutics, Inc. Transaction History
Artal Group S.A.
- $1.58 Billion
- Q2 2024
A detailed history of Artal Group S.A. transactions in Tango Therapeutics, Inc. stock. As of the latest transaction made, Artal Group S.A. holds 2,519,841 shares of TNGX stock, worth $14.9 Million. This represents 1.37% of its overall portfolio holdings.
Number of Shares
2,519,841
Previous 2,194,841
14.81%
Holding current value
$14.9 Million
Previous $17.4 Million
24.06%
% of portfolio
1.37%
Previous 0.94%
Shares
2 transactions
Others Institutions Holding TNGX
# of Institutions
121Shares Held
89.1MCall Options Held
2.6KPut Options Held
1K-
Trv Gp Iv, LLC Boston, MA19.2MShares$114 Million81.48% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA13.3MShares$78.9 Million4.04% of portfolio
-
Boxer Capital, LLC San Diego, CA8.2MShares$48.5 Million3.91% of portfolio
-
Nextech Invest Ag5.53MShares$32.8 Million8.96% of portfolio
-
Southpoint Capital Advisors LP New York, NY5.28MShares$31.2 Million1.32% of portfolio
About Tango Therapeutics, Inc.
- Ticker TNGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 88,067,296
- Market Cap $521M
- Description
- Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...